selegiline has been researched along with md 230254 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernard, S; Burstein, C; Curet, O; Gueddari, S; Lebreton, L; Mazouz, F; Milcent, R | 1 |
| Burstein, C; Gueddari, S; Mansuy, D; Mazouz, F; Milcent, R | 1 |
2 other study(ies) available for selegiline and md 230254
| Article | Year |
|---|---|
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
Topics: Animals; Brain; Female; Male; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles | 1995 |
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors.
Topics: Animals; Binding, Competitive; Brain; Kinetics; Male; Mitochondria; Molecular Structure; Monoamine Oxidase Inhibitors; Oxadiazoles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 1993 |